Clinical Trials

qaqa27

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

org1

During Phase 1 of the Study, newly pregnant mothers will be enrolled less than or equal to 20 weeks + 6 days gestation and followed through to the end of pregnancy. Prenatal urine and buccal (cheek) samples will be collected to measure urinary herbicide exposure levels and to identify herbicide induced epigenetic biomarkers. Pregnancy outcomes and fetal health will be documented and analyzed to further investigate potential effects of fetal exposure. Indirect measures such as food and beverage consumption, workplace and household related chemical exposures, substance use, residential proximity to agricultural fields, and socioeconomic factors will be captured from questionnaires.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEMS) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults of cancer usually consists of getting advice from their doctor. This advice may include how to do their daily activities, so they are less tired or how to manage multiple diseases, or long-term side effects from treatment. GEMS may help improve the physical ability to perform activities of daily living, mental well-being, and memory in older survivors of cancer after chemotherapy. This study may help doctors learn if including GEMS in their practices improves physical, mental and memory functions in their patients. The study may also help to understand how such care affects cancer patients and their caregivers' quality of life.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This is a Prospective Observational Cohort Study, designed to better characterize patients with cancer cachexia (CC) by prospectively evaluating weight, muscle mass, fat mass, eating and appetite, physical function, symptoms, and associated medical and biopsychosocial factors. CC was defined by an international consensus panel as a “multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment1.” CC has been associated with reduced physical performance, impaired quality of life and poorer survival. Unfortunately, there currently are no Food and Drug Administration (FDA)-approved treatment for CC. Therefore, therapeutic development for CC is an urgent unmet need. The diagnostic criteria for CC as defined by the international consensus are as follows: a) greater than 5% weight loss in the previous 6 months or b) greater than 2% weight loss with either low Body Mass Index (BMI) or skeletal muscle depletion. A key criticism of the diagnostic criteria is that it is too broad and simplistic for a complex, multifactorial disease process and that it relies too heavily on weight, which is subject to change from a myriad of conditions. The aim of this study will be to develop new diagnostic criteria for CC subtypes so that pathophysiologic drivers of CC can be isolated in individuals and, ultimately, more tailored therapies can be developed.

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Rice Lake

2501 Main

Stevens Point, WI 54481

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin and nal-IRI (plus trastuzumab for HER2-positive tumors) as first-line therapy for patients with advanced EGA. Subjects will be enrolled into one of the two cohorts based on the HER2 status of the tumor. Subjects in Cohort 1 (HER2-negative) will be treated with 5-FU, oxaliplatin and nal-IRI. Subjects in Cohort 2 (HER2-positive) will be treated with trastuzumab in addition to 5-FU, oxaliplatin and nal-IRI.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - Eau Claire

2116 Craig Rd

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

A very large pragmatic trial that will examine the effects of statins on dementia prevention in the elderly. The first statin trial with a non-CVD primary outcome - survival free of dementia or persisting disability. Using a placebo-controlled pragmatic clinical trial (PCT) design across PCORnet and Veterans Affairs health care systems, we will evaluate the risks and benefits of a moderate-intensity statin on important health outcomes for older adults.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Velos_Test_01042023

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This multi-center, prospective, observational, feasibility study is designed to compare data collected by two FDA-cleared wearable devices: a) the Rhythm Express Wearable System, and b) Polysomnography (PSG).

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team/Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - River Region at Stevens Point

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476